Pfizer Inc. (NYSE:PFE) Shares Acquired by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust boosted its holdings in Pfizer Inc. (NYSE:PFE) by 5.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,904 shares of the biopharmaceutical company’s stock after acquiring an additional 2,749 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Pfizer were worth $1,424,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. boosted its holdings in shares of Pfizer by 3.8% in the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 945 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Pfizer by 3.1% during the 4th quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 899 shares in the last quarter. Gryphon Financial Partners LLC increased its position in shares of Pfizer by 43.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 8,194 shares during the period. E Fund Management Co. Ltd. lifted its holdings in shares of Pfizer by 22.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 13,922 shares of the biopharmaceutical company’s stock valued at $401,000 after buying an additional 2,514 shares during the period. Finally, Principal Securities Inc. bought a new position in Pfizer during the fourth quarter valued at about $2,393,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Up 0.4 %

Shares of PFE stock traded up $0.11 during trading on Friday, hitting $28.62. 5,385,224 shares of the company were exchanged, compared to its average volume of 38,178,727. The business’s 50-day simple moving average is $29.05 and its 200 day simple moving average is $28.04. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.64. The firm has a market capitalization of $162.18 billion, a price-to-earnings ratio of -475.09, a P/E/G ratio of 1.02 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.67 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were paid a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.87%. Pfizer’s payout ratio is -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.